A single dose of recombinant adenoviral vector rabies vaccine expressing two copies of glycoprotein protects mice from lethal virus challenge
The Journal of Infection in Developing Countries · 2024
DOI: 10.3855/jidc.19193 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Infection in Developing Countries, 2024. Verfasst von Qunlong Li und 5 weiteren Autor:innen. Beteiligte Einrichtung: Chengdu Kanghua Biological Products Co., Ltd. Chengdu 610100, Sichuan, China. Hauptthemen laut MEDLINE: Rabies Vaccines, Rabies, Vaccines, Synthetic, Genetic Vectors. Die Arbeit wurde bisher 2-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
Rabies is a fatal infectious disease, that poses a major public health threat in developing countries. With an annual death toll of approximately 59,000, more than half of which are children, an urgent need exists for a safe, affordable, and effective preventive measure against rabies virus infection. Methodology: A recombinant rabies vaccine called Ad5-dRVG was constructed by introducing two copies of the rabies virus glycoprotein into a human adenoviral vector. Virus-neutralizing assays and virus challenge experiments were employed to evaluate the Ad5-dRVG vaccine.
Results
Our findings demonstrate that a single dose of Ad5-dRVG, administered either intramuscularly or orally, elicited significantly stronger immune responses than Ad5-RVG. Moreover, both vaccines provided complete protection in mice. Notably, the vaccine exhibited remarkable efficacy even at low doses, suggesting potential cost reduction in production.
Conclusions
The development of the Ad5-dRVG recombinant rabies vaccine represents a significant advancement in rabies prevention. Its enhanced immunogenicity, demonstrated efficacy and potential cost savings make it a promising candidate for widespread use.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Chengdu Kanghua Biological Products Co., Ltd. Chengdu 610100, Sichuan, China.
Zitieren
APA
Li, Q., He, H., Zhou, Y., Wang, J., Chen, H., & Liu, H. (2024). A single dose of recombinant adenoviral vector rabies vaccine expressing two copies of glycoprotein protects mice from lethal virus challenge. The Journal of Infection in Developing Countries. https://doi.org/10.3855/jidc.19193
Vancouver
Li Q, He H, Zhou Y, Wang J, Chen H, Liu H. A single dose of recombinant adenoviral vector rabies vaccine expressing two copies of glycoprotein protects mice from lethal virus challenge. The Journal of Infection in Developing Countries. 2024. doi:10.3855/jidc.19193
BibTeX
@article{Li2024,
author = {Li, Qunlong and He, Hongzhuan and Zhou, Yuxi and Wang, Jihong and Chen, Huan and Liu, Hui},
title = {A single dose of recombinant adenoviral vector rabies vaccine expressing two copies of glycoprotein protects mice from lethal virus challenge},
journal = {The Journal of Infection in Developing Countries},
year = {2024},
doi = {10.3855/jidc.19193}
}
EUVIMED